PersonExecutiveScientist
Blaine McKee
Blaine McKee is the president and CEO of Walden Biosciences, a Cambridge, Massachusetts biotech building first-in-class medicines that go after the kidney itself instead of just slowing the road to dialysis. A chemist turned dealmaker turned operator, he launched Walden with a $51 million Series A in 2020 and now steers two clinical-stage programs: WAL0921, an anti-suPAR antibody, and WAL0623, a small-molecule dynamin stabilizer. Before Walden he spent 15 years at Genzyme and held top corporate-development roles at Shire and ImmunoGen, pairing an MIT organic-chemistry PhD with an MIT Sloan finance MBA.
blaine mckeewalden biosciencesbiotech ceokidney diseasedrug discoverysuPAR